Rick Shinto Continues To Improve InnovaCare Health

Since 2012 InnovaCare Health has been under the leadership of company CEO Dr. Richard Shinto. Rick Shinto’s over 20 years in the healthcare industry has made him an authority in managed healthcare. He brings years of technical experience as well as proven leadership skills to InnovaCare in his position as company president. InnovaCare Health is a leading provider of managed healthcare services in North America, including Medicare Advantage and Medicaid programs. InnovaCare and their affiliates remain dedicated to bringing quality healthcare to its many clients, located throughout North America and Puerto Rico.

Before joining InnovaCare, Rick Shinto served in several other prestigious healthcare positions. He was the Chief Medical Officer for Cal Optima Health, the Chief Medical Officer for Medical Pathways Management and served as president and CEO of Aveta Inc. During his tenure with Aveta Rick was awarded a very prestigious award, he was named the recipient of the Ernst & Young Entrepreneur of the year. The awarded given to individuals who have displayed a commitment to excellence in their respective fields. Read this article at Open Minds.

Rick Shinto believes teamwork and transparency are behind the success of InnovaCare. Excellent communication and a clear vision of the future coupled with a proper working relationship are what it takes to be successful in the future. Rick Shinto and InnovaCare Health are redefining the management of managed healthcare in today’s ever-changing healthcare environment. He is considered the driving force behind the ongoing changes and improvements at InnovaCare that will make it possible for the company to expand into other markets in the future. All this will ultimately lead to better patient benefits and care.

In Puerto Rico, InnovaCare Health works out of two affiliates. The company operates MMM Healthcare Inc. and PMC Medicare Choice Inc.; both programs offer quality medical care programs designed to give their clients both physical and emotional wellbeing. The two affiliates enjoy an approval rate of 90 percent and have received an NCQA accreditation. To be considered for this certification, a company must meet or exceed the recognized requirements of a quality healthcare program. Read more about Rick Shinto on BusinessWire.Com

Rick Shinto has a B.S. degree from the University of California, earned his medical degree at the University of New York and received his M.B.A. from the University of Redlands. After graduation, Rick began his career as a pulmonologist in Southern California. He has authored many articles and received several awards for his work in the managed healthcare industry.

Oncotarget Is Rising In Popularity

The peer-review in Oncotarget has been quite insightful. This has helped to maximize the advantages of research. This has led to its rising popularity. The peer reviews are constructive and punctual. Besides, there are multiple peer-reviews, and this helps the authors a lot.

The members of its Editorial Board are an accomplished lot. This would include Carlo M. Croce. He is the former Editor-in-Chief of Cancer Research. Next is Andrew Schally. He is an accomplished Nobel Prize winner. Both of them have published 27 as well as 10 papers respectively in this, Oncotarget.

4 members of Oncotarget/Oncoscience/Gerotarget are the winners of the Breakthrough Prize. This is the highest prize, and it is a record achievement too. The winners are Bert Vogelstein, besides Michael N. Hall, and Alexander Varshavsky along with Stephen J. Elledge.

Oncotarget is the sponsor for the Gordon Research Conference. It is highly popular. This is why today Oncotarget is accepting papers that are on topics which are beyond oncology. They would include subjects such as neuroscience, endocrinology, besides cardiology and metabolism. Other subjects include cell biology, other areas of pharmacology and so on. The journal is peer reviewed and is published by Impact Journals.

Oncotarget has made a special offer. For those who feel that their paper has been mistakenly rejected by any other leading journal, they can submit it to Oncotarget. They need to do so along with the peer-reviews from the other journal and the rebuttal letter too.

It is the term “oncotarget” that says it all. It denotes all molecules, their pathways, the cellular functions which are common in cancer aging and in neuro-degeneration too. Along with this is atherosclerosis, lymphocytes besides neurons along with cancer cells and microbes.

Today Oncotarget is considered as a multidisciplinary journal allowing free-access. Oncotarget is now publishing its papers online. There are weekly issues that are coming out. Any issue or paper can be printed on special demand.

The mission here is to ensure easy and fast access to scientific results. This way Oncotarget will be able to maximize this impact of research. All this can be made possible only through having an insightful review. This would allow the sharing of exceptional discoveries. All this can now be done quickly. The borders between specialties also disappear this way. Oncotarget is also available on Dove Press.